Immune cells engineered to attack solid tumors enter human testing
NCT ID NCT07152236
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 28 times
Summary
This study tests a new treatment called B7H3 CAR-T cell therapy for people with advanced solid tumors that have a specific marker (B7H3). The therapy uses the patient's own immune cells, modified in a lab to better find and kill cancer cells. About 20 participants will receive the treatment and be followed for up to one year to see if tumors shrink and to monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dongguan Taixin Hospital
RECRUITINGDongguan, Guangdong, 523125, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.